Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Doctor Group Warns Of Kala Azar Spread In India, Southeast Asia

This article was originally published in PharmAsia News

Executive Summary

An official of Medecins Sans Frontieres warned Southeast Asian governments they need to make drugs more accessible to the poor as visceral leishmaniasis spreads and becomes treatment-resistant. The international group's tropical medical adviser said the disease, transmitted by sand flies, has an effective treatment in Ambisome (liposomal amphotericin B), shown to be 98 percent effective so far. But, she said, it and other drugs to fight the disease are not available to the people who need them most. At a conference in India where the potentially fatal disease is endemic, she called for it to be included in India's treatment protocol as a first-line option. (Click here for more

You may also be interested in...



Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

Commission Regulatory Advice For COVID-19 Medtech Sector Entrants Amid Counterfeit Concerns

A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.

Commission’s One-Year MDR Delay Text Contains EU-Wide Derogation Proposals Too

The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.

UsernamePublicRestriction

Register

SC070975

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel